Letrozole and Lapatinib in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery

Status: Recruiting
Phase: Phase 2
Diagnosis: Breast: Early Stage Disease
NCT ID: NCT00499681 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 08-165

 

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving letrozole together with lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This randomized phase II trial is studying how well giving letrozole together with lapatinib works in treating postmenopausal women with stage I, stage II, or stage III breast cancer that can be removed by surgery.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Beth-Israel Deaconess Medical Center

Overall PI:
Ian Krop, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Steven Come, MD, Beth Israel Deaconess Medical Center

Contacts:
Brigham and Women's Hospital: Aaron Welch, 617-582-7264, aawelch@partners.org
Beth-Israel Deaconess Medical Center: Cancer Trials Call Center, 617-667-3060

Eligibility Criteria

DISEASE CHARACTERISTICS: Inclusion - Clinical stage I, II, or III operable invasive mammary carcinoma, confirmed by histological analysis - Measurable residual tumor at the primary site - Measurable disease is defined as any mass that can be reproducibly measured by physical examination, mammogram, and/or ultrasound and can be accurately measured in at least one dimension (longest diameter to be recorded) as 10 mm (1 cm) - Available core biopsies from the time of diagnosis - May include sections of paraffin-embedded material - Scheduled to undergo surgical treatment with either segmental resection or total mastectomy - Prior history of contralateral breast cancer allowed if patient has no evidence of recurrence of their initial primary breast cancer within the last 5 years - HER2-positive by Herceptest (3+) or FISH - ER-positive and/or PR-positive by IHC Exclusion - Locally recurrent breast cancer - Evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases) PATIENT CHARACTERISTICS: Inclusion - Female - Postmenopausal, as defined by any of the following: - At least 55 years of age - Under 55 years of age and amenorrheic for at least 12 months OR follicle-stimulating hormone (FSH) values ≥ 40 IU/L and estradiol levels ≤ 20 IU/L - Prior bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months - ECOG performance status 0-1 - ANC ≥ 1,000/mm³ - Platelet count ≥ 100,000/mm³ - Creatinine ≤ 1.5 times upper limit of normal (ULN) - Bilirubin ≤ 1.5 times ULN - AST and ALT ≤ 1.5 times ULN - Able to swallow and retain oral medication - Cardiac ejection fraction normal by echocardiogram (or MUGA scan if an echocardiogram cannot be performed or is inconclusive) Exclusion - Premenopausal breast cancer, pregnant, or lactating - Serious medical illness, that in the judgment of the treating physician, places the patient at high risk of operative mortality - Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel - Ulcerative colitis - History of other malignancy - Patients who have been disease-free for 5 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinomas are eligible - Active or uncontrolled infection - Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent - Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure PRIOR CONCURRENT THERAPY: Exclusion - Prior chemotherapy for primary breast cancer - Tamoxifen or raloxifene as a preventive agent within the past 21 days - Hormone replacement therapy (e.g., conjugated estrogens tablets [Premarin]) within the past month - Prior therapy with anthracyclines - Investigational drug within the past 30 days or 5 half-lives, whichever is longer - Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, or any other biologic therapy) other than letrozole - Concurrent treatment with an investigational agent
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms